<DOC>
	<DOCNO>NCT01016574</DOCNO>
	<brief_summary>The purpose study evaluate Giro-couch , innovative patient support device application prone RT treatment breast cancer . This study assess feasibility new position approach facilitate delivery external beam , deliver lumpectomy cavity , ( boost dose , partial breast therapy ) .</brief_summary>
	<brief_title>Evaluating Adequacy Giro-Couch Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT .</brief_title>
	<detailed_description>Treatments apply subject supine position , ~50 Gy per treatment ( ~2GY per fraction ) , period five six week . Energy use usually 6-15MV photon . Following whole breast irradiation , boost dose give lumpectomy cavity , order reduce local recurrence immediate vicinity treat breast . The boost dose usually applied electron , 6-18MEV . Sixteen Gy usual dose , 2 Gy/Fx , 8 fraction .</detailed_description>
	<criteria>Women satisfy follow condition patient eligible study : The patient must consent study must sign approve consent form conform federal institutional guideline . Patients must ≥ 40 year old . The patient must stage I II breast cancer . If stage II , tumor size must 3 cm less . Surgical treatment breast must lumpectomy . The margin resect specimen must least 2mm . Reexcision surgical margin permit . Gross disease must unifocal . The target lumpectomy cavity must clearly delineate target lumpectomy cavity/whole breast reference volume must ≤ 30 % base treatment plan CT scan . The lumpectomy cavity must delineate surgical clip surgeon . Patients eligible , base postoperative/ simulation CT scan , prone boost RT judge technically deliverable prone breast IMRTIGRT technique . Patients history nonbreast malignancy eligible diseasefree 5 year prior randomization deem physician low risk recurrence . Patients follow cancer eligible diagnose treat within past 5 year : carcinoma situ cervix , carcinoma situ colon , melanoma situ , basal cell squamous cell carcinoma skin . Men eligible study . Women one follow condition also ineligible study . T0 , T2 ( &gt; 3.0 cm ) , T3 , stage III , stage IV breast cancer ( see Appendix A TNM nomenclature stag ) . Suspicious microcalcifications , density , palpable abnormality ( ipsilateral contralateral breast ) unless biopsied found benign . Nonepithelial breast malignancy sarcoma lymphoma . Proven multicentric carcinoma ( invasive cancer DCIS ) one quadrant separate 4 centimeter . Paget 's disease nipple . Synchronous bilateral invasive noninvasive breast cancer . Surgical margin microscopically assess positive pathologic evaluation . ( If surgical margin render free disease reexcision , patient eligible . ) Clear delineation extent target lumpectomy cavity possible . Breast implant . Prior breast thoracic RT condition Collagen vascular disease , specifically dermatomyositis , systemic lupus erythematosis , scleroderma . Pregnancy lactation time propose randomization . Women reproductive potential must agree use effective nonhormonal method contraception therapy . Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>